Quinine sulfate as a therapeutic option in a patient with slow channel congenital myasthenic syndrome.

Abstract excerpt

Slow channel congenital myasthenic syndrome is caused by a genetically determined kinetic anomaly of the acetylcholine receptor at the neuromuscular junction leading to its prolonged open state. Patients typically present with fatigability and static weakness of neck, hand and finger extensors. The open-channel blockers fluoxetine and quinidine have been used as standard treatment, although the former is limited...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mutation
• Share to Myasthenic Syndromes, Congenital